title: Anti-TNF-alpha treatment and bile duct drainage restore cellular immunity and prevent tissue injury in experimental obstructive jaundice.
abstract: Several experimental studies of obstructive jaundice (OJ) have shown the presence of immunosuppressive state associated with the rise of tumor necrosis factor-alpha (TNF-alpha) concentration in plasma. The present study evaluates the impact of anti-TNF- alpha administration or bile duct drainage on the inflammatory response, liver injury and renal insufficiency in obstructed rats. OJ was induced by the ligation of bile duct in Wistar rats. The parameters were determined at 14 and 21 days after OJ. Two additional groups of animals were treated with anti-TNF-alpha antibodies or submitted to bile duct drainage at 14 days, and sacrificed 21 days after OJ. Cholestasis decreased glucose, and enhanced urea, creatinin, bilirubin and transaminases. Cholestasis increased the number of different inflammatory cells (T and B lymphocytes, and monocytes-macrophages) but reduced the expression of the corresponding cellular activation markers. This low responsiveness of the inflammatory cells was related to a decreased free radical production and phagocytic activity of cells. Anti-TNF-alpha and bile duct drainage reduced tissue injury, and prevented the reduction of the number and activity of T lymphocytes and phagocytic cells observed at the advanced stages of cholestasis. In conclusion, anti-TNF- alpha and bile duct drainage improved cell immunodeficiency, and reduced liver injury, cholestasis and renal insufficiency in experimental OJ.
authors.affiliation: Department of General Surgery, Reina Sofia University Hospital, Ciberehd, Córdoba, Spain.
authors.forename: F J
authors.initials: FJ
authors.lastname: Padillo
authors.forename: A
authors.initials: A
authors.lastname: Cruz
authors.forename: I
authors.initials: I
authors.lastname: Segura-Jiménez
authors.forename: J
authors.initials: J
authors.lastname: Ruiz-Rabelo
authors.forename: M R
authors.initials: MR
authors.lastname: Vázquez-Ezquerra
authors.forename: M D
authors.initials: MD
authors.lastname: Perea-Alvarez
authors.forename: J
authors.initials: J
authors.lastname: Peña
authors.forename: J
authors.initials: J
authors.lastname: Briceño
authors.forename: J
authors.initials: J
authors.lastname: Muntané
mesh_terms: D000818:Animals; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D001652:Bile Ducts; D002779:Cholestasis / Q000209:etiology / Q000517:prevention & control; D003131:Combined Modality Therapy; D004322:Drainage; D005434:Flow Cytometry; D005609:Free Radicals / Q000378:metabolism; D006505:Hepatitis / Q000209:etiology / Q000517:prevention & control; D007154:Immune System Diseases / Q000209:etiology / Q000276:immunology; D007111:Immunity, Cellular / Q000502:physiology*; D007249:Inflammation / Q000473:pathology; D041781:Jaundice, Obstructive / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008297:Male; D010587:Phagocytosis / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D019138:Antibodies, Blocking; D005609:Free Radicals; D014409:Tumor Necrosis Factor-alpha